Global Schizophrenia Therapeutics Market 20172021 [Report Updated: 26072017] Prices from USD $3500

05:00 EDT 2 Aug 2017 | BioPortfolio Report Blog

About Schizophrenia Therapeutics
Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.

Technavio's analysts forecast the global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 20172021.

Covered in this report
The report covers the present scenario and the growth prospects of the global schizophrenia therapeutics market for 20172021. To calculate the market size, the report considers the sales of branded, generic, and offlabel drugs.

The market is divided into the following segments based on geography:

Technavio's report, Global Schizophrenia Therapeutics Market 20172021, has been prepared based on an indepth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Eli Lilly
Johnson Johnson
Other prominent vendors
BristolMyers Squibb
Market driver
Increasing expenditure on prescription drugs
For a full, detailed list, view our report

Market challenge
Technological advances in noninvasive neuromodulation devices
For a full, detailed list, view our report

Market trend
Increase in use of LAI antipsychotic drugs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Original Article: Global Schizophrenia Therapeutics Market 20172021 [Report Updated: 26072017] Prices from USD $3500


More From BioPortfolio on "Global Schizophrenia Therapeutics Market 20172021 [Report Updated: 26072017] Prices from USD $3500"

Quick Search

Relevant Topics

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Schizophrenia is a common  serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...